Materials & Resources » Chemicals | Cambrex Corp.

Cambrex Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
318,309.00
374,427.00
433,931.00
490,338.00
535,006.00
531,185
Cost of Goods Sold (COGS) incl. D&A
215,272.00
250,815.00
256,361.00
286,419.00
304,369.00
335,405
Gross Income
103,037.00
123,612.00
177,570.00
203,919.00
230,637.00
195,780
SG&A Expense
57,955.00
65,564.00
70,407.00
73,874.00
87,369.00
84,053
EBIT
45,082.00
50,878.00
107,163.00
130,045.00
143,268.00
111,727
Unusual Expense
-
-
15,573.00
1,998.00
-
1,884
Non Operating Income/Expense
3,985.00
960.00
659.00
209.00
190.00
161
Interest Expense
1,798.00
1,709.00
1,366.00
717.00
1,253.00
3,967
Pretax Income
45,007.00
45,506.00
89,565.00
127,539.00
141,825.00
109,805
Income Tax
14,732.00
12,627.00
32,389.00
40,214.00
38,061.00
16,596
Consolidated Net Income
30,275.00
58,133.00
57,176.00
87,325.00
103,764.00
93,209
Net Income
30,275.00
58,133.00
57,176.00
87,325.00
103,764.00
93,209
Net Income After Extraordinaries
34,635.00
58,963.00
57,135.00
92,972.00
105,078.00
94,000
Net Income Available to Common
25,915.00
57,303.00
57,217.00
81,678.00
102,450.00
92,418
EPS (Basic)
0.84
1.81
1.76
2.48
3.06
2.75
Basic Shares Outstanding
30,150.00
30,763.00
31,420.00
32,086.00
32,662.00
33,243
EPS (Diluted)
0.84
1.81
1.76
2.48
3.06
2.75
Diluted Shares Outstanding
30,901.00
31,643.00
32,555.00
32,969.00
33,486.00
33,665
EBITDA
67,555.00
74,704.00
129,224.00
154,710.00
175,116.00
149,584
Other Operating Expense
-
7,170.00
-
-
-
-
Equity in Affiliates (Pretax)
2,262.00
4,623.00
-
-
-
-

About Cambrex

View Profile
Address
One Meadowlands Plaza
East Rutherford New Jersey 07073
United States
Employees -
Website http://www.cambrex.com
Updated 07/08/2019
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates.